Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2017-11-12 Capital/Financing Update
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Appendix 3B 16 pages 147.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including classes of securities, number of securities issued, issue price, purpose of the issue, and application for quotation of additional securities on the ASX. It references ASX rules and compliance with the Corporations Act. The content is consistent with a formal announcement related to capital raising or share issuance rather than a full financial report or earnings release. The document is lengthy (15,000 characters) and contains detailed regulatory and procedural information about the new issue and quotation of shares. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2017-11-12 English
Initial Director's Interest Notice 2 pages 60.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, including the appointment date of the director and securities interests. This type of document is a report of personal share transactions or interests by company directors, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, not financial results or other report types.
2017-11-06 English
Lifespot Health restructures its Business and Board 2 pages 137.9KB
Board/Management Information Classification · 95% confidence The document is an announcement from Lifespot Health regarding changes in its business structure and board composition, including resignations and new appointments of directors. It discusses management changes and strategic focus but does not contain financial statements, detailed financial performance data, or regulatory filings. The document length is 3751 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on board and management changes rather than financial results or other report types. Therefore, the most appropriate classification is Board/Management Information (MANG).
2017-10-31 English
Final Director's Interest Notice 2 pages 80.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's cessation date and securities interests, which are typical elements of a director's dealing or interest notice. The content focuses on the director's relevant interests in securities and related contracts, with no financial performance data or report content. The document length is short (2366 characters) and is a formal notice of director's interests rather than a financial report or announcement of a meeting or vote. Therefore, it fits the category of Director's Dealing (DIRS).
2017-10-31 English
Final Director's Interest Notice 2 pages 80.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of a director and the director's relevant interests in securities, with no securities held. This is a report of personal share transactions or holdings by a company director, which fits the definition of Director's Dealing filings. The document length is short and focused solely on director interests, not a broader financial or management report.
2017-10-31 English
Appendix 4C - quarterly 6 pages 1.0MB
Interim / Quarterly Report Classification · 100% confidence The document is titled as an Appendix 4C Quarterly report for the quarter ended 30 September 2017, which is a standard quarterly cash flow report required by the ASX Listing Rule 4.7B. It contains detailed financial data including cash flows from operating, investing, and financing activities, cash balances, and estimated cash outflows for the next quarter. The document is about 9,883 characters long, which is substantive and contains actual financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement or a certification but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2017
2017-10-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.